Business Wire

Hao Le Ku (Beijing) Infant and Maternity Co., Ltd. Announces the Launch in Hong Kong of Halykoo ® Line Developed by the Swiss Company APR Applied Pharma Research

Jaa

Halykoo® baby healthcare consumer products are now available in Hong Kong, promoted and commercialized by the Chinese company Hao Le Ku (HLK), as a result of an exclusive partnership with APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products.

Hong Kong baby and child-specific products market is expected to grow at a CAGR of 2% in the next years, mainly driven by the local demand and a high per capita income. Hong Kong market is very dynamic with sophisticated consumers, historically used to international brands, being very sensitive to innovative and value added products as well as looking for brands which can offer them new meaningful experiences.

Halykoo® brand, the babies’ healthcare expert, matches the request coming from such a demanding market, as its science-driven solutions are the perfect combination of Swiss, high-quality pharmaceutical expertise with an extensive understanding of child and caregivers needs.

Halykoo® offers to parents a new way for the daily healthcare of their children, by turning a potentially stressful moment into a pleasant and rewarding experience, thanks to smart and innovative product deliveries intended to simplify their use for parents and reduce the hassle for babies.

In the first phase of launching, the distribution will focus mainly on baby and health stores that offer specialized health products and health counselling. In addition, HLK will start to build up their own online store, targeting young and highly-educated parents who are digital lovers with high purchasing power. Universal Health International Group Holding Limited has been appointed by HLK as the only distributor in Hong Kong and Macao district.

Supporting Halykoo® line at best for brand building and grapping a significant share of market, HLK has carried out a comprehensive media and communication campaign, with a specific focus on online marketing as well as social networks according to the digital mindset of the potential target. In addition, special promotions will be arranged in different distribution points through trained promoters, to introduce to young mothers Halykoo® products.

“We’re investing a lot on Halykoo® launch as we mean to build up a strong brand awareness and achieve a remarkable market share in the first year,” said Mr. Ricky Ren CEO of HKL. “We really want Halykoo® to be a great success in Hong Kong as this could be the stepping stone towards Great China.”

To celebrate the launch, HLK has participated to the 25th Eugene Baby Expo, one of the biggest international B2C baby-related exhibition, from 4th to 7th August in Wan Chai. The exhibition, held twice a year, had a record of over 500,000 visits and 800 exhibitors in average, thus being the perfect showcase for Halykoo® product range.

“We are very proud to see Halykoo® products on Hong Kong stores shelves – said Mr. Paolo Galfetti, CEO of APR – and we strongly believe that Halykoo® Swiss quality products will be soon appreciated by Hong Kong consumers, in a market where baby and child-specific products saw a steady growth in 2016. ”

About Halykoo®
Halykoo®, the babies’ healthcare expert, is the first global brand offering the most comprehensive range of consumer healthcare products. It matches formulations s specifically focused on each of the main stages of children’s growth, since birth, with smart and innovative deliveries intended to simplify their use for parents and reduce the hassle for babies.

The product range has been carefully developed to solve the main daily babies’ healthcare discomforts in the major therapeutic areas for turnover such as skin care, cough & cold, eye, ear & mouth and food supplementation. As of today, the portfolio includes over 18 already developed products and 10 additional products are under development to be finalized in 2018.

Conceived and formulated applying the value of Swiss pharmaceutical expertise, Halykoo provides science-driven pediatric solutions that perfectly combine smart deliveries, thanks to the application of the pharmaceutical technology knowledge, with advanced formulations, balanced on the physiological babies’ needs.

For more info about Halykoo®, please visit: www.halykoo.com

About Hao Le Ku (Beijing) Infant and Maternity Co., Ltd.
Hao Le Ku is a leading company engaged in marketing of baby products. We are a service oriented, high quality and ethically-driven. Our company was founded in 2013 and registered in Tian Jin, China. Our revenue has been increasing significantly during the last 2 years and the growth rate recorded is more than 100%. Our baby protection products covered many different categories in the industry.

About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science-driven, patent protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products commercialized in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.
For more information please visit www.apr.ch or www.halykoo.com

Contact information

APR Applied Pharma Research s.a.,
Paolo Galfetti; CEO
T: +41 91 6957020
email to paolo.galfetti@apr.ch
or
Hao Le Ku (Beijing) Infant and Materniity Co., Ltd.
Ricky Ren; CEO
T: +1 (626) 328-9241
email to renhongguang@halykoo.com.cn
or
Havas PR Milan - Press Office
Sara Bernabovi
T: +39 02 85457032 or email to
sara.bernabovi@havaspr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC26.9.2018 11:00Tiedote

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC). The survey results will be presented today as a late-breaking abstract (P3.01-108) at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada. The two most important treatment goals identified by those surveyed were increasing overall survival (OS) (77%), followed by quality of life (QoL) (69%), irrespective of the line of treatment. Findings show that more than half (55%) of physicians strongly preferred a treatment sequence that offers patients the maximum time on targeted treatments. Furthermore, physicians reported that there is a strong need for information on potential treatment resistance mutations before changing their current treatment pract

Easy Visual Launches App For Targeted Advertising Reach Through Smartphones26.9.2018 10:00Tiedote

Easy Visual has launched Banners App - a mobile application that shows targeted banners ads to users when they unlock their smartphones. Recent Boston Consulting Group research indicates that consumers spend 25% of their total offline and online media consumption time on mobile phones. However, advertisers spend only 12% of their budgets on mobile ads. Mobile advertising is unappreciated by some brands and it results in a loss of potential clients. Easy Visual has decided to change the situation. 69% of consumers from 18 to 39 years old use smartphones to look for products before buying them. Banners App offer brands and advertisers ads shown only to their target audiences, real views, statistics on the number of views and the conversion rate. Companies get potential customers, brand recognition and better ROI. It avoids brand reputational loss, because users voluntarily look at the advertising messages. Easy Visual is an innovative advertising network that provides advertisers and bra

SoftAtHome Invests in Quality of Experience for Fixed-Mobile Convergence by Acquiring V3D, Leader in Telecom Data Analytics26.9.2018 10:00Tiedote

SoftAtHome, the software company dedicated to the digital home, and V3D, a leading independent software vendor expert on Telecom data analytics for carrier network operators, announced today the signing of an acquisition agreement. With SoftAtHome acquiring V3D, the company will be able to deliver a full range of solutions around “analytics for Quality of Experience” for its fixed and mobile operator clients, by relying on the millions of data points collected by V3D. Thanks to both companies’ expertise, skills and solutions, Carrier Network Operators will benefit from a global value proposition on improving Customer Experience on their fixed and mobile networks. David VIRET-LANGE, Chief Executive Officer of SoftAtHome, commented: “In an increasingly digital world, consumers expect seamless connectivity with their mobile and tablets wherever they are. Quality of Experience will be naturally measured by the same solutions. The V3D solution portfolio and expertise on mobile and fixed net

NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate26.9.2018 09:05Tiedote

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “We are pleased that we continue to see results from real-world studies in line with our randomized pivotal study, demonstrating that the UroLift System is a safe and effective minimally invasive treatment that offers men long-term relief from the symptoms of BPH.” Five Studies Show Significant Relief and Improved Quality of Life with UroLift Sy

NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care26.9.2018 09:05Tiedote

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “This analysis of the UroLift System demonstrates its transformative impact on BPH care within a major health system,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “These real-world results continue to support the safety and efficacy of the UroLift System findings of our pivotal trial, and also suggest that the adoption of the UroLift System can save health systems millions in reduced organizational costs when compared to the traditional invasive surgical TURP procedure for patients with BPH.” U.K. Data Suggests UroLift System Greatly Reduces Costs Associated with TURP The Transforming BPH Surgi

Oliver Wyman Supports Inclusion Initiative in the Nordics26.9.2018 09:00Tiedote

Oliver Wyman announced today a new partnership with Ashoka, the world’s largest network for social entrepreneurs, to support a new inclusion fund called Hello Nordics. This fall, ten social entrepreneurs – eight from Denmark, Finland, Norway and Sweden and two internationals – will kick off a large-scale inclusion effort across the Nordic region. The entrepreneurs each bring their own unique approach to fostering integration and inclusion. Their common goal: to scale their solutions to better both social and financial inclusion of marginalized people in the Nordic region. The ten entrepreneurs have all been carefully selected based on their ability to address root causes in a systemic way, by involving policy makers, lawmakers, communities and target groups. The participants are Catalysts (NO), Sisters in Business (NO), Foreningen Nydansker (DK), GAME (DK), Startup Refugees (FI), Icehearts (FI), Mitt Liv (SE), Idrott Utan Gränser (SE), Welcoming International (USA/Germany) and ACAF/Win

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme